TOTAL ALLERGY CARE for HEALTH PROFESSIONALS

Clinical Data

ZYRTEC® significantly relieves ocular allergy symptoms in SAR patients*1

Significant relief shown from Day 1 of treatment*1

  • Continued ocular symptom relief was demonstrated in daily analysis of Total Ocular Symptom Score (TOSS) during the first week of treatment

Significant improvement continued over the 2-week treatment period*1

  • 35% to 62% mean improvement from baseline in ocular scores vs placebo

*Randomized, placebo-controlled studies of SAR patients (N=1255). Total Ocular Symptom Score (TOSS) was the sum of the severity scores for itchy eyes and watery eyes; one study also included red eyes. Individual symptom scores were rated on a 4-point scale (0=none to 3=severe).

SAR 1 was 1 week in duration.

Reference: 1. Patel M, Urdaneta E, Franklin K, et al. Cetirizine significantly relieves ocular allergy symptoms in subjects with seasonal allergic rhinitis. Poster Abstract. Data on file, Johnson & Johnson Consumer Inc.

ZYRTEC® significantly relieves nasal allergy symptoms in SAR patients*1

Significant relief of TNSS shown from Day 1 of treatment*1

  • Daily analysis of mean Total Nasal Symptom Score (TNSS) in the first week of ZYRTEC® 10mg treatment demonstrated continued improvement in nasal symptoms

Significant improvement continued over the 2-week treatment period*1

  • 29% to 63% mean improvement from baseline in nasal severity scores

*Randomized, placebo-controlled studies of SAR patients (N=921). Total Nasal Symptom Score (TNSS) was the sum of the severity scores for sneezing, runny nose, itchy nose in all studies; two studies included post-nasal discharge. Individual symptom scores were rated on a 4-point scale (0=none to 3=severe).

SAR 1 was 1 week in duration.

Reference: 1. Urdaneta E, Tian X, Wu M, et al. Cetirizine effectively relieves both ocular allergy symptoms and nasal allergy symptoms in subjects with seasonal allergic rhinitis. Poster Abstract. Data on file, Johnson & Johnson Consumer Inc.

ZYRTEC® starts working fast to relieve symptoms

In 2 EEU studies*: ZYRTEC® worked 3 times faster than Claritin® (1 hour vs 3 hours)†1,2

*The environmental exposure unit (EEU) is an indoor chamber used to expose large groups of subjects to controlled levels of pollen comparable to those experienced outdoors during peak allergy season, and can be replicated regardless of time of year. The EEU is a validated, standard method of determining onset of action and duration of anti-allergic treatments.

ZYRTEC® 10mg starts working at hour 1 and Claritin® starts working at hour 3, based on first dose on the first day of a 2-day study in 2 pollen chamber studies. Primary endpoint measured mean improvement from baseline in Major Symptom Complex (MSC) severity score. MSC symptoms included runny nose, sniffles, itchy nose, nose blows, sneezes, and watery eyes.

All third-party trademarks are the property of their respective owners.

References: 1. Day JH, Briscoe M, Widitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998;101(5):638-645. 2. Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87(6):474-481.

ZYRTEC® significantly improved quality of life (QoL) in adult SAR patients*1-3

Patients receiving ZYRTEC® reported significantly greater improvements in overall RQLQ scores compared with placebo

The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a validated measurement of overall QoL. These studies used the 28-item RQLQ, which measured 7 domains: activity limitation, sleep problems, nose symptoms, eye symptoms, non–hay fever symptoms, practical problems, and emotional function.

Download the PDF to view the PAR data and more.

*Two multicenter, randomized, double-blind, placebo-controlled studies including 1254 adult SAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.

Adult RQLQ assessed domains on a 7-point (0-6) rating scale.4

Endpoint = last post-baseline observation.

References: 1. Data on file, Johnson & Johnson Consumer Inc. 2. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):391-398. 3. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCI in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;3(3):351-358. 4. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjuntivitis. Clin Exp Allergy. 1991;21(1):77-83.

Clinical Data Investigator

Gather clues and use the data to help patients relieve their allergy symptoms.

Clinical data investigator Clinical data investigator Clinical data investigator

More clinical data on ZYRTEC®

Here are additional clinical data on the efficacy and tolerability of ZYRTEC®

Clinical data Clinical data Clinical data

ZYRTEC® products

See the complete family of ZYRTEC® products.

ZYRTEC Products ZYRTEC Products ZYRTEC Products